JP2016532667A - ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ - Google Patents

ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ Download PDF

Info

Publication number
JP2016532667A
JP2016532667A JP2016521758A JP2016521758A JP2016532667A JP 2016532667 A JP2016532667 A JP 2016532667A JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016532667 A JP2016532667 A JP 2016532667A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
immunomodulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016521758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532667A5 (OSRAM
Inventor
スティーヴン・ノーマン・クエイル
サイモン・スチュワート・ジョーンズ
ケネス・シー・アンダーソン
テル・ヒデシマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acetylon Pharmaceuticals Inc
Original Assignee
Acetylon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acetylon Pharmaceuticals Inc filed Critical Acetylon Pharmaceuticals Inc
Publication of JP2016532667A publication Critical patent/JP2016532667A/ja
Publication of JP2016532667A5 publication Critical patent/JP2016532667A5/ja
Priority to JP2018225287A priority Critical patent/JP7403950B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016521758A 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ Pending JP2016532667A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018225287A JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361889640P 2013-10-11 2013-10-11
US61/889,640 2013-10-11
US201361911089P 2013-12-03 2013-12-03
US61/911,089 2013-12-03
PCT/US2014/059387 WO2015054175A1 (en) 2013-10-11 2014-10-07 Combinations of histone deactylase inhibitors and immunomodulatory drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018225287A Division JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Publications (2)

Publication Number Publication Date
JP2016532667A true JP2016532667A (ja) 2016-10-20
JP2016532667A5 JP2016532667A5 (OSRAM) 2017-11-16

Family

ID=52810182

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016521758A Pending JP2016532667A (ja) 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Country Status (17)

Country Link
US (2) US20150105358A1 (OSRAM)
EP (1) EP3054939A4 (OSRAM)
JP (4) JP2016532667A (OSRAM)
KR (1) KR20160060143A (OSRAM)
CN (1) CN105722507A (OSRAM)
AU (1) AU2014332147A1 (OSRAM)
CA (1) CA2926808A1 (OSRAM)
CL (1) CL2016000838A1 (OSRAM)
CR (1) CR20160200A (OSRAM)
EA (1) EA201690753A1 (OSRAM)
IL (1) IL244923A0 (OSRAM)
MX (1) MX2016004604A (OSRAM)
NI (1) NI201600051A (OSRAM)
PE (1) PE20161342A1 (OSRAM)
PH (1) PH12016500649A1 (OSRAM)
SG (1) SG11201602791RA (OSRAM)
WO (1) WO2015054175A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019052171A (ja) * 2013-10-11 2019-04-04 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2020500200A (ja) * 2016-11-23 2020-01-09 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ−ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
JP2020504086A (ja) * 2016-11-23 2020-02-06 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933558B (zh) 2010-01-22 2016-03-16 埃斯泰隆制药公司 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
NZ710405A (en) 2010-11-16 2017-04-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
ES2929576T3 (es) * 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
EP3055299B1 (en) * 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
KR20160092018A (ko) 2013-12-03 2016-08-03 에이스틸론 파마수티컬스 인코포레이티드 히스톤 탈아세틸화효소 저해제 및 면역조절 약물의 조합
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
AU2015288060A1 (en) 2014-07-07 2017-02-09 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
AU2015356779A1 (en) 2014-12-05 2017-07-13 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
US9790180B2 (en) 2014-12-12 2017-10-17 Regenacy Pharmaceuticals, Llc Piperidine derivatives as HDAC1/2 inhibitors
CA2988594C (en) 2015-06-08 2023-08-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
EP3303306B1 (en) 2015-06-08 2020-02-12 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
US11311540B2 (en) * 2016-02-17 2022-04-26 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
EP3445364A4 (en) 2016-04-19 2019-11-27 Acetylon Pharmaceuticals, Inc. HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
EP3468559B1 (en) * 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
CR20220325A (es) 2019-12-20 2022-08-19 Tenaya Therapeutics Inc Fluoroalquil-oxadiazoles y sus usos
JP2024514356A (ja) 2021-04-23 2024-04-01 テナヤ セラピューティクス， インコーポレイテッド 拡張型心筋症の治療に使用するためのｈｄａｃ６阻害剤
KR20240016950A (ko) 2021-05-04 2024-02-06 테나야 테라퓨틱스, 인코포레이티드 대사 질환 및 hfpef의 치료에 사용하기 위한 2-플루오로알킬-1,3,4-옥사디아졸-5-일-티아졸, hdac6 억제제
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528973A (ja) * 2003-05-15 2006-12-28 セルジーン・コーポレーション ３−（４−アミノ−１−オキソ−１，３−ジヒドロイソインドール−２−イル）−ピペリジン−２，６−ジオンの多形相を含む、ガン治療用医薬組成物
WO2012068109A2 (en) * 2010-11-16 2012-05-24 Acetylon Pharmaceuticals Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2361619A1 (en) * 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
CN102933558B (zh) * 2010-01-22 2016-03-16 埃斯泰隆制药公司 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
EP2734500A4 (en) 2011-07-20 2015-04-08 Gen Hospital Corp SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
EP3054939A4 (en) * 2013-10-11 2017-12-13 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528973A (ja) * 2003-05-15 2006-12-28 セルジーン・コーポレーション ３−（４−アミノ−１−オキソ−１，３−ジヒドロイソインドール−２−イル）−ピペリジン−２，６−ジオンの多形相を含む、ガン治療用医薬組成物
WO2012068109A2 (en) * 2010-11-16 2012-05-24 Acetylon Pharmaceuticals Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 118, no. 21, JPN6018023903, 2011, pages 128, ISSN: 0003985326 *
ＰＯＭＡＬＹＳＴ（登録商標）添付文書, JPN6018023905, February 2013 (2013-02-01), ISSN: 0003985325 *
ＲＥＶＬＩＭＩＤ（登録商標）添付文書, JPN6018023904, February 2013 (2013-02-01), ISSN: 0003985324 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019052171A (ja) * 2013-10-11 2019-04-04 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP7403950B2 (ja) 2013-10-11 2023-12-25 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2020500200A (ja) * 2016-11-23 2020-01-09 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ−ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
JP2020504086A (ja) * 2016-11-23 2020-02-06 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
JP7090611B2 (ja) 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
JP2022095809A (ja) * 2016-11-23 2022-06-28 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
JP2022095820A (ja) * 2016-11-23 2022-06-28 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
JP7516047B2 (ja) 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
JP2024116134A (ja) * 2016-11-23 2024-08-27 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法

Also Published As

Publication number Publication date
JP2024010118A (ja) 2024-01-23
EA201690753A1 (ru) 2016-07-29
JP7403950B2 (ja) 2023-12-25
CL2016000838A1 (es) 2016-11-25
CA2926808A1 (en) 2015-04-16
IL244923A0 (en) 2016-05-31
MX2016004604A (es) 2016-08-01
CR20160200A (es) 2016-08-29
JP2019052171A (ja) 2019-04-04
WO2015054175A1 (en) 2015-04-16
PE20161342A1 (es) 2016-12-31
JP2021073314A (ja) 2021-05-13
AU2014332147A1 (en) 2016-05-05
US20200323849A1 (en) 2020-10-15
EP3054939A1 (en) 2016-08-17
CN105722507A (zh) 2016-06-29
PH12016500649A1 (en) 2016-05-30
SG11201602791RA (en) 2016-05-30
NI201600051A (es) 2017-07-11
US20150105358A1 (en) 2015-04-16
EP3054939A4 (en) 2017-12-13
KR20160060143A (ko) 2016-05-27

Similar Documents

Publication Publication Date Title
JP7403950B2 (ja) ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
EP3054953B1 (en) Hdac inhibitors in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
JP6535670B2 (ja) ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
JP6626437B2 (ja) ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
US9833466B2 (en) Treatment of leukemia with histone deacetylase inhibitors
US20150105409A1 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma
US9937174B2 (en) Combinations of histone deacetylase inhibitors and bendamustine
WO2017143237A1 (en) Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171003

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190304